Literature DB >> 2725296

Cystathionine-synthase-deficient patients do not use the transamination pathway of methionine to reduce hypermethioninemia and homocystinemia.

H J Blom1, G H Boers, J M Trijbels, J J van Roessel, A Tangerman.   

Abstract

Methionine is supposed to be degraded via two known routes, the transsulfuration and the transamination pathways. In particular, patients with hypermethioninemia, due to a defect in the transsulfuration pathway, may catabolize significant amounts of methionine via the transamination pathway. In this study the relative amount of methionine degraded via the transamination pathway in 17 patients with homozygous homocystinuria, due to cystathionine synthase deficiency, was compared with 23 normal subjects, and with a patient with hypermethioninemia due to a deficiency in methionine adenosyltransferase. The homocystinuric patients and the normal subjects were studied in the fasting state as well as after methionine loading (0.1 g/kg body weight). It is concluded that in cystathionine synthase deficient patients, the transamination pathway is not quantitatively important in methionine degradation despite elevated methionine levels. This is in contrast to the patient with methionine adenosyltransferase deficiency, who catabolizes at least 20% of his dietary methionine via the transamination pathway.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2725296     DOI: 10.1016/0026-0495(89)90220-5

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  6 in total

Review 1.  The biochemical and toxicological significance of hypermethionemia: new insights and clinical relevance.

Authors:  Joseph T Dever; Adnan A Elfarra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-09-28       Impact factor: 4.481

2.  Gender differences in methionine accumulation and metabolism in freshly isolated mouse hepatocytes: potential roles in toxicity.

Authors:  Joseph T Dever; Adnan A Elfarra
Journal:  Toxicol Appl Pharmacol       Date:  2009-02-21       Impact factor: 4.219

3.  Persistent hypermethioninaemia with dominant inheritance.

Authors:  H J Blom; A J Davidson; J D Finkelstein; A S Luder; I Bernardini; J J Martin; A Tangerman; J M Trijbels; S H Mudd; S I Goodman
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

4.  Alternative methionine degradation via the transamination pathway: an option for therapy for homocystinuria due to cystathionine synthase deficiency.

Authors:  H J Blom; G H Boers; A Tangerman; W A Gahl; J M Trijbels
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

5.  Isolated persistent hypermethioninemia.

Authors:  S H Mudd; H L Levy; A Tangerman; C Boujet; N Buist; A Davidson-Mundt; L Hudgins; K Oyanagi; M Nagao; W G Wilson
Journal:  Am J Hum Genet       Date:  1995-10       Impact factor: 11.025

6.  Adenosine kinase deficiency: expanding the clinical spectrum and evaluating therapeutic options.

Authors:  Christian Staufner; Martin Lindner; Carlo Dionisi-Vici; Peter Freisinger; Dries Dobbelaere; Claire Douillard; Nawal Makhseed; Beate K Straub; Kimia Kahrizi; Diana Ballhausen; Giancarlo la Marca; Stefan Kölker; Dorothea Haas; Georg F Hoffmann; Sarah C Grünert; Henk J Blom
Journal:  J Inherit Metab Dis       Date:  2015-12-07       Impact factor: 4.982

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.